- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Oncology
Volume 2010 (2010), Article ID 928628, 14 pages
Inhibition of Melanoma Angiogenesis by Telomere Homolog Oligonucleotides
1Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
2Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Chicago, IL 60611, USA
3Division of Cardiovascular Research, Department of Medicine, Center of Cancer Systems Biology, Caritas St. Elizabeth's Medical Center of Boston, MA 02135, USA
Received 13 November 2009; Revised 6 May 2010; Accepted 7 May 2010
Academic Editor: Arkadiusz Dudek
Copyright © 2010 Christina Coleman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Telomere homolog oligonucleotides (T-oligos) activate an innate telomere-based program that leads to multiple anticancer effects. T-oligos act at telomeres to initiate signaling through the Werner protein and ATM kinase. We wanted to determine if T-oligos have antiangiogenic effects. We found that T-oligo-treated human melanoma (MM-AN) cells had decreased expression of vascular endothelial growth factor (VEGF), VEGF receptor 2, angiopoeitin-1 and -2 and decreased VEGF secretion. T-oligos activated the transcription factor E2F1 and inhibited the activity of the angiogenic transcription factor, HIF-1. T-oligos inhibited EC tubulogenesis and total tumor microvascular density matrix invasion by MM-AN cells and ECs in vitro. In melanoma SCID xenografts, two systemic T-oligo injections decreased by 60% () total tumor microvascular density and the functional vessels density by 80% (). These findings suggest that restriction of tumor angiogenesis is among the host's innate telomere-based anticancer responses and provide further evidence that T-oligos may offer a powerful new approach for melanoma treatment.
Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis  and inhibition of angiogenesis is an important new approach for therapy of many cancers [1, 2]. A principal regulator of angiogenesis is vascular endothelial growth factor (VEGF) . The VEGF family is comprised of at least five genes (VEGF A through E), of which the most potent activators of angiogenesis are VEGF-A and VEGF-B . Analysis of the VEGF-A (termed VEGF here and elsewhere in the text) gene promoter region has revealed numerous potential transcriptional activator sites . One of the best studied stimuli for VEGF synthesis and secretion is hypoxia, which acts by upregulating hypoxia inducible factor-1 (HIF-1) . Inhibition of HIF-1 may therefore decrease angiogenesis by reducing VEGF levels and potentially other proangiogenic factors, such as angiopoeitin-1 and -2 (Ang-1 and Ang-2) [6–8], basic fibroblast growth factor (bFGF), and platelet derived growth factor (PDGF), all well known regulators of angiogenesis .
The role of E2F1 in apoptosis is well recognized. It can act in concert with p53 or independent of p53 to induce apoptosis . T-oligos, telomere homolog oligonucleotides, activate p53 and E2F1, resulting in apoptosis . However, in p53 null cells like malignant melanoma AN cells (MM-AN), apoptosis is induced by the p53 homolog p73 , presumably acting coordinately with E2F1. Moreover, E2F1 has also been reported to inhibit angiogenesis [9, 12]. While E2F1 decreases VEGF production in fibroblasts through p53 activation , its effect on angiogenesis in cells that lack functional p53, such as MM-AN cells has not been studied [11, 13].
Several lines of evidence suggest that normal cells have an integrated program of genome-protective responses, functionally analogous to the bacterial SOS response , that is based in the telomeres and appears to be abrogated in malignancy . Telomeres, the ends of chromosomes, are maintained in a loop configuration by insertion of the single-stranded overhang into the proximal telomere duplex . Disruption of this loop structure by removal of the principal binding protein TRF2 (telomere repeat binding factor 2) leads to exposure and digestion of the overhang and activation of ATM (ataxia telangiectasia mutated) and its effector protein p53, followed by apoptosis or senescence, depending on cell type . Knockdown of another telomere-associated protein, the protection of telomeres-1 (POT-1), also expected to expose the TTAGGG telomere repeat sequence, activates ATR (ataxia telangiectasia and Rad3-related), leading to similar downstream effects [16, 17]. Moreover, treatment of malignant cells with RNAi to knockdown the expression of TER, the RNA subunit of telomerase, rapidly alters the expression of many genes in a pattern predicted to reduce cancer cell proliferation and invasiveness , then leads to apoptosis in a time course far too rapid to be attributable to the expected loss of telomerase activity and consequent telomere shortening, suggesting that other telomere-based effects are responsible .
Our laboratory has described several anticancer properties of oligonucleotides homologous to the telomere repeat sequence TTAGGG (T-oligos) [10, 11, 13, 15, 19–28]. T-oligos provided to cultured cells rapidly accumulate in the nucleus and mediate DNA damage responses without digestion of the telomere overhang or other detectable effects on genomic DNA [10, 13, 15, 19, 23, 25, 26, 29]. T-oligos activate the ATM kinase [21, 27], upregulate and activate p53 [30, 31], as well as upregulate and/or activate its homolog p73, E2F1, p, p33, p27, and p95/Nbs1, and phosphorylate the histone variant protein H2AX [11, 13, 21, 22, 24, 25]. In addition, T-oligos promote differentiation of melanoma cells and downregulate the inhibitor of apoptosis protein IAP/livin in these cells . T-oligo effects require WRN , the protein mutated in the progeroid cancer-prone Werner syndrome , and are associated with formation of classic DNA damage foci at telomeres . In combination, these signaling cascades result in induction of apoptosis, autophagy, and/or senescence selectively in cancer cells [13, 19, 27, 28]; while in normal cells they lead to transient cell cycle arrest, increased DNA repair capacity and adaptive differentiation [19, 21, 23, 25–27, 30]. Complementary, unrelated, or scrambled oligonucleotides comparably accumulate in the nucleus, but do not cause DNA damage-like signaling or affect growth, differentiation or survival of malignant cells [11, 13, 15, 19, 21, 24, 27, 28].
Because the T-oligo-induced transcription factors p53, p73, and E2F1 are known to affect endothelial cell (EC) survival, differentiation, and proliferation during tumor angiogenesis [12, 33, 34] and because blocking angiogenesis would be an additional anticancer mechanism of action for T-oligos, we asked whether T-oligo treatment inhibits tumor angiogenesis. We now report that T-oligo inhibits angiogenesis in the aggressive human melanoma cell line MM-AN, derived from a metastatic melanoma , by decreasing production and secretion of proangiogenic factors in both tumor cells and ECs. As well, T-oligo treatment decreases the number of total and functional (perfused) vessels in flank tumors of MM-AN cells in SCID mice after two systemic injections.
2. Materials and Methods
2.1. Cell Cultures
Human microvascular endothelial cells (HMVECs) and human umbilical vein endothelial cells (HUVECs) were obtained at passage 2 and used by passage 4–6. Cells were maintained in EGM-2 medium with 2% FBS plus growth factors (bullet kit) (Cambrex Bio Sciences, Walkersville, MD). Human melanoma MM-AN and EP cells  were cultured in modified Eagle’s medium (MEM) (Mediatech, Inc., Herndon, VA) supplemented with fetal bovine serum (FBS 2%), calf serum (CS 8%), and antibiotic-antimicotic. Human breast adenocarcinoma (MCF-7) and ovarian adenocarcinoma (OVCAR3) cells were cultured and maintained according to ATCC recommendations. All cells were incubated at with 5% CO2.
We used a 16-base 100% telomere homolog with the sequence -GTTAGGGTTAGGGTTA- and phosphodiester backbone. The oligonucleotide was synthesized by Midland Certified Reagent (Midland, TX) and then diluted from a 2 mM stock in medium to obtain a final concentration of 40 M.
2.3. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
MM-AN, EP, MCF-7, and OVCAR3 cells were grown in their corresponding media and treated once with diluent or 40 M T-oligo. For qRT-PCR, we performed a reverse transcription reaction then amplified specific genes as described . mRNA expression levels were assessed for E2F1, ANG-1, and ANG-2. The sequences used were as follows: E2F1 forward: CGGTGTCGTCGACCTGAACT, E2F1 reverse: AGGACGTTGGTGATGTCATAGATG, E2F1 probe: TGCCGAGGTGCTGAAGGTGCAG; ANG-1 forward: CAGAAAACAGTGGGAGAAGATATAACC, ANG-1 reverse: TGCCATCGTGTTCTGGAAGA, ANG-1 probe: CAACATGGGCAATGTGCCTACACTTTC; ANG-2 forward: GGCTGGGCAATGAGTTTGTC, ANG-2 reverse: CCCAGTCCTTCAGCTGGATCT; ANG-2 probe: ACCGGTCAGCACCGCTACGTGC.
2.4. Electromobility Shift Assay (EMSA)
Cells were treated with diluent or 40 M T-oligo and harvested 0, 1, 16, and 32 hours after treatment. EMSAs were carried out as described  using a total of 5 g of nuclear protein per lane. The assay was performed using consensus sequences of E2F1 and HIF-1 transcription factors (Santa Cruz Biotechnology, CA). The specificity of the bands was confirmed by using either 25 or 50 excess of cold probe as competitor and mutant oligos as control. As an additional negative control, nuclear extracts were incubated with a specific competing E2F1 antibody before adding the radioactive (32P-labelled) consensus oligonucleotides.
2.5. Western Blot Analysis
Cells were treated with T-oligos, harvested at various times, snap-frozen, and stored at . Total cellular protein was isolated and 50 g of total protein was processed for western blot analysis as described . Antibody reactions were performed with the following antibodies: anti-E2F1 (Neomarkers, Inc., Fremont, CA), anti-VEGF-A (sc-507, Santa Cruz Biotechnology, Inc, Santa Cruz, CA) that recognizes all VEGF-A isoforms, and anti-VEGF-R2 (a kind gift from Dr. Nader Rahimi, Departments of Ophthalmology and Biochemistry, Boston University School of Medicine).
2.6. VEGF Enzyme-Linked Immunosorbent Assay (ELISA)
The Human VEGF Immunoassay kit (Quantikine, R&D Systems, Minneapolis, MN) was used to compare the release of VEGF into the medium by ECs and MM-AN cells. Each cell type was cultured in its appropriate medium and treated with either diluent or T-oligo (40 M). The conditioned medium was collected at 24, 48, and 72 hours after treatment and frozen at until it processed for ELISA. The assay was performed according to the manufacturer’s protocol (R&D Systems). The plate was read using the Tecan Spectra model 96 Well Microplate Reader (MTX Lab Systems, Vienna, VA).
2.7. Tubulogenesis Assay
200 L of Matrigel basement membrane matrix (phenol-red free) (BD Biosciences, Bedford, MA) was added per 4-well chamber slide and allowed to solidify for 1 hour at . HUVECs (50,000 cells) were then added to each chamber in 500 L of medium as described . Cells were treated at the time of plating with diluent, 40 M, 80 M, or 120 M of T-oligo. Some of the cells treated with 40 M of T-oligo were retreated a second time at 2 hours postplating, at the time tube-formation could first be detected by phase microscopy. Some cells that were treated twice with 40 M of T-oligo received a third treatment 6 hours after plating. Tube-formation was observed and photographed at numerous time points starting from 2 hours and up to 24 hours after treatment. Of note, after tubular structures formed in control wells, they stayed intact up to 72 hours (data not shown). Image-Tool (The University of Texas Health Science Center in San Antonio, San Antonio, TX) software was used to quantify the length of tubular structures.
2.8. Invasion Assay
The BioCoat Matrigel Invasion Chamber (BD Biosciences, Bedford, MA) was used for this assay. MM-AN cells were treated with diluent or 40 M T-oligo and media were collected after 72 hours, based on ELISA data (MM-AN conditioned media). Conditioned MM-AN medium was then used as the chemoattractant for the assay. ECs and MM-AN cells were grown on the inserts (upper chambers) and allowed to invade through the Matrigel and attach to the membrane as described in the manufacturer’s protocol. Invasion was assessed after 22 hours by staining with Diff-Quick (Fisher, Atlanta, GA) bisected membranes from the bottom of the chambers (containing the invading cells) as described in the manufacturer’s protocol. Of note, we believe that any effect on ECs or MM-AN invasion cannot be attributed to residual active T-oligos in the conditioned medium, diffusing into the upper chamber and killing MM-AN cells, because T-oligos are rapidly degraded in serum-containing medium. With a measured half-life for a 12-base telomere homolog of 4–6 hours , the 16-base T-oligo would thus have been present in the medium after 72 hours of conditioning at an estimated (1/2)12 or 107-fold less than the initial therapeutic concentration.
2.9. SCID Melanoma Flank Xenograft Model
All studies were approved by Boston University’s IACUC Committee. MM-AN cells were injected subcutaneously into the flank of 6 week old SCID mice (Fox-Chase Cancer Center, Philadelphia, PA). Mice (5-6 per treatment group) were injected via tail vein with T-oligo or diluent alone when tumors were first palpable (2-3 mm diameter). Tumor sizes were recorded every 2-3 days throughout the experiment using electronic callipers and all animals were sacrificed 4 weeks after tumor inoculation. The diagnosis of melanoma was confirmed histologically on sections of each nodule cut through the center of the clinical tumor.
2.10. Quantification of Tumor Microvessel Density
All studies were approved by Boston University’s IACUC Committee. MM-AN cells were injected subcutaneously into the flank of 6 week old SCID mice (Fox-Chase Cancer Center, Philadelphia, PA). Then mice (5-6 per treatment group) were injected via the tail vein with T-oligo or diluent alone (60 nmoles/injection, 15 mg/kg) when tumors were first palpable (2-3 mm diameter). Microvascular density (MVD) in bisected tumors were assessed 24 hours after two systemic injections of T-oligos by using two EC-specific markers CD31 (PECAM-1)  and Bandeurea simplicifolia (BS)-1 lectin conjugated to Rhodamine (Vector Laboratories, Burlingame, CA) . To measure functional MVD in the tumor tissue, 30 minutes before sacrifice a set of mice (5 per treatment group) were anesthetized and were perfused with 0.5 mg (in 100 l of isotonic solution) of Rhodamine-conjugated BS-1 lectin as described [40, 41]. To measure total MVD, 6 m cross-sections of bisected tumor tissue (of the same mice perfused with BS-1 lectin) were stained with CD31 primary antibody followed by FITC-labelled secondary antibody as described . Samples were photographed using a multicolour fluorescence microscope (Nikon, Nikon Instruments Inc, Melville, NY), and analyzed using a digital image analysis system (Nikon). The diagnosis of melanoma was confirmed histologically in tumor sections of each nodule.
2.11. Statistical Analysis
ANOVA with post hoc analysis by Scheffe and Bonferroni-Dunn and unpaired t-Test were performed using StatView (SAS Institute, Inc., Version 5.0). Statistical significance was established at .
3.1. T-oligo Treatment Decreases the Expression and Level of Angiogenic Factors and Reduces VEGF Release into MM-AN Cell Medium
MM-AN cells were treated once with T-oligo or diluent alone, provided in fresh medium, and processed for western blot analysis. Compared to diluent, T-oligo decreased VEGF protein level at 24 hours () by 41% and at 48 hours () by 32% (Figures 1(a) and 1(b)). In addition, after 48 hours T-oligo treatment reduced ANG-1 mRNA () by 60% (Figure 1(c)) and ANG-2 mRNA () by 45% (Figure 1(d)). Similar decreases in VEGF (Supplemental Figures (a)–(c) and ANG-1 (Supplemental Figures (a)–(c)) mRNA were seen in a second human melanoma line EP, as well as in other malignant cell types.
Paired dishes of MM-AN and ECs were treated with 40 M T-oligo or diluent alone once. Medium was collected after 24, 48 and 72 hours and VEGF level in the medium was measured by ELISA. In ECs (HMVEC and HUVEC), there was a 50%–75% variable and statistically insignificant decrease in VEGF release into the medium over time in both diluent- and T-oligo-treated cells (data not shown). In contrast, total VEGF release from MM-AN cells in diluent-treated dishes rose progressively over 72 hours to 600% (of 24-hours VEGF levels), while VEGF release in T-oligo-treated dishes was decreased () by 30% over the 72-hours experiment after a single dosing at time 0 (Figure 1(e)). Thus, T-oligo not only decreased VEGF protein expression in tumor cells but also the release of this potent angiogenic factor into the surrounding culture medium.
3.2. T-oligo Upregulates E2F1 Gene Expression, Protein Level, and DNA Binding Activity and Decreases the DNA Binding Activity of the Angiogenic Transcription Factor HIF-1
E2F1 mRNA expression was increased at 24 hours () by 41% and at 48 hours () by 100% in T-oligo-treated MM-AN cells compared to control (Figure 2(a)). Similar increases in E2F1 mRNA were seen in a second human melanoma line EP, as well as in other malignant cell types (Supplemental Figures (a)–(c)). T-oligo treatment also increased E2F1 protein level at 24 hours to 218% and at 48 hours to 286% () of control values (Figures 2(b) and 2(c)). In addition, there was a doubling in E2F1 DNA binding activity 32 hours after treatment compared to diluent-treated cells (Figures 2(d) and 2(e), compare lane 3 versus 4).
MM-AN cells were treated once with T-oligo or diluent alone and nuclear proteins were harvested up to 32 hours after treatment to evaluate DNA binding activities of the angiogenic transcription factor HIF-1. There was 80%–95% decrease in HIF-1 DNA binding activity at 1 and 16 hours after treatments (Figures 2(f) and 2(g), lanes 3 versus 4, and 5 versus 6, respectively). These data suggest that T-oligo-mediated inhibition in DNA binding activity of HIF-1 transcription factor contributes to decreased expression of the angiogenic factors, VEGF and ANG-1, whose promoters contain binding sites for HIF-1 .
3.3. T-oligo Inhibits Matrigel Invasion by Melanoma Cells and ECs
We used MM-AN medium collected 72 hours after addition of T-oligo or diluent alone (MM-AN conditioned media: T-oligo CM or diluent CM) as the chemoattractant for an in vitro invasion assay . MM-AN and HMVECs were both evaluated for invasion through Matrigel to determine if T-oligo treatment reduces the chemoattractant properties of MM-AN cells. As recommended by the manufacturer of the Matrigel invasion kit, after 22 hours of incubation the invading cells were fixed, stained and counted for each membrane. MM-AN cells plated above T-oligo CM had a 96% decrease in invasion () through Matrigel (Figures 3(a) and 3(b)). HMVECs plated on inserts coated with Matrigel and exposed to T-oligo CM had a 40% reduction in Matrigel invasion compared to controls, but this did not reach statistical significance () (Figures 3(c) and 3(d)). These findings demonstrate that T-oligos reduce the migration/invasion of MM-AN cells towards chemoattractant stimuli and, possibly, to a lesser degree affect HMVECs. This is consistent with the observation that MM-AN cells elaborate factors that promote migration and invasion of tumor cells, like VEGF and ANG-1, and that these factor(s) are reduced as a result of T-oligo treatment.
3.4. T-oligo Treatment Decreases the Expression of VEGF and VEGFR-2 in Endothelial Cells
Because VEGF signaling through VEGFR-2 is principally responsible for EC survival, proliferation, migration, and angiogenesis [44–47], we examined the effect of T-oligo treatment on these proteins. HMVECs and HUVECs were grown and treated with 40 M T-oligo or diluent alone. Compared to diluent-treated control cells there was a decrease () of 86% in VEGF expression at 24 hours and an insignificant decrease of 50% at 48 hours in T-oligo-treated samples (Figures 4(a)–4(c)). In addition, in T-oligo-treated HMVECs and HUVECs there were 29% () and 59% () reduction in the protein level of VEGFR-2 at 24 and 48 hours, respectively (Figures 4(d)–4(f)). Thus, T-oligo-mediated antiangiogenic effects on ECs may be, in part, due to inhibition of VEGF-VEGR2 axis.
3.5. T-oligo Inhibits EC Function In Vitro in Tubulogenesis Assay
HMVECs were plated on Matrigel in 4-well chamber slides in serum-containing medium and treated with diluent alone or increasing concentrations of T-oligo. Tube-like structure formation was maximal in controls at 22 hours and formal comparisons were made after 2–22 hours, as customary for this assay . By 22 hours, in cells treated once with either 40 M or 80 M T-oligo there was a 19% reduction in average tube length compared to cells treated with diluent alone () (Figures 5(a) and 5(b)). Cells treated with two separate doses of 40 M T-oligo at plating and 2 hours after plating showed a 35% reduction in average tube length (). Cells treated once at plating with 120 M T-oligo showed a 58% reduction in average tube length compared to the diluent-treated cells (). A reduction of 83% () in tube length was observed in cells treated with 3 separate doses of 40 M T-oligo (40 M 3) added to the medium at the time of plating and then at 2 and 6 hours (Figures 5(a) and 5(b)). These results indicate that T-oligo inhibits EC function in a manner dependent on the dose and frequency of administration, with the caveat that the very large amount of oligos administered, rather that specific telomere-based T-oligo initiated signalling may have contributed to the effect observed. In our future experiments, we plan to examine the effect of large and/or fractioned T-oligo doses on survival of ECs.
3.6. Systemic Administration of T-oligo Reduces Tumor Angiogenesis and Vessel Patency In Vivo in a SCID Mouse Xenograft Model
In melanoma tumors inoculated into SCID mice, we determined the effect of systemic T-oligo injection on melanoma angiogenesis by evaluating functional and total vessel density in tumor tissue (5 mice per group). When tumors became palpable (2-3 mm in diameter, day 5 to 14 after inoculation) we injected T-oligo (60 nmoles/injection, 15 mg/kg) via the tail vein (IV) and injected again after 6 hours, then harvested tumors 24 hours after the second T-oligo injections. Representative images of tumor cross-sections were immunostained to identify all vessels as well as functional (patent) vessels 24 hours after T-oligo injection (Figure 6(a)). Compared to control-injected mice there was more than 80% decrease () in functional vessels in T-oligo-injected mice (Figure 6(b)). There was also more than 60% decrease () in total vessels in T-oligo-injected mice (Figure 6(c)). These data corroborate our in vitro findings (Figures 4 and 5) and demonstrate that two systemic administrations of T-oligo reduce tumor angiogenesis and vessel patency in vivo (Figures 6(a)–6(c)).
To determine the effect of systemic T-oligo treatment on melanoma growth, in SCID xenograft model MM-AN cells were injected subcutaneously in the flank. When tumors became palpable (2-3 mm in diameter, day 5 to 14), the mice received daily systemic injections of T-oligo (60 nmoles/injection, 15 mg/kg BID) or vehicle for 5 days only. In control animals, tumors increased in volume from 6.96 2.9 mm3 on day 6 to 88.04 19.72 mm3 on day 27 (Figure 6(d), blue line). In contrast, in T-oligo treated animals, whose tumors were the same size as in controls on day 6 (6.48 2.57) there was very little tumor growth through day 15 (6.48 2.57 versus 9.92 3.8 mm3) and thereafter a slower and statistically insignificant increase in volume to 29.65 10.47 mm3 by day 27 (Figure 6(d), pink line). Thereby, in T-oligo-treated mice tumor growth was inhibited () by 53% after 4 weeks, when the experiment was terminated. These data demonstrate that systemic administration of T-oligo for only 5 days has a persistent inhibitory effect on melanoma growth. We have also evaluated T-oligos toxicity in several internal organs of SCID mice 24 hours after the last IV injections (15 mg/kg BID for 5 days). No systemic toxicity was observed in bone marrow, liver, intestines, brain, lungs and kidneys of T-oligo-injected mice (Figures 7(a)–7(f)).
Tumor angiogenesis is essential for tumor growth and metastasis . Without active angiogenesis tumor diameter rarely exceeds 2-3 mm [1, 48]. Angiogenesis is mediated through release of angiogenic factors by tumor cells and cells in the tumor stroma and microenvironment including, but not limited to, endothelial cells . We now report that telomere homolog oligonucleotides (T-oligos) decrease the synthesis and release of angiogenic factors by ECs and melanoma cells, inhibit EC tubulogenesis and impede melanoma cells and ECs from invading matrix (Matrigel). In addition, systemic administration of T-oligos decreases tumor vascularity in vivo.
EC migration, proliferation and differentiation are all essential processes for tumor angiogenesis . EC proliferation, in vitro tubulogenesis, and survival are all known to be stimulated in large part by VEGF . Decreased VEGF levels or inhibition of receptor activation in ECs often correlate with decrease in tumor size and metastatic potential . VEGF binds to the extracellular domain of the VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1), inducing receptor dimerization and activation of tyrosine kinases by autophosphorylation, leading to angiogenesis, increased vascular permeability, and EC proliferation and survival . It is generally accepted that VEGFR-2 is the major mediator of these effects . We found that T-oligo decreases the expression of VEGFR-2 by HMVEC and HUVEC (Figures 4(c) and 4(f)). Other investigators reported that receptor tyrosine kinase inhibitors (TKIs) such as sunitinib and dasatinib reduce signaling through the RAF/MEK/ERK pathway that is activated by ligand binding to angiogenic receptors like VEGFR-2, PDGFR-, FH-3 and c-kit , indirectly inhibiting tumor growth by affecting tumor angiogenesis . By reducing VEGF-R2 level, T-oligos appear to have similar effects.
VEGF also induces leakage within tumor vessels, allowing tumor cells to infiltrate blood vessels and migrate into the blood stream . Hence, changes in angiogenic factors even early in tumor formation can affect metastasis and spread  and inhibiting VEGF production by T-oligos would be expected to reduce the metastatic potential of tumor cells . Additionally, increased blood vessel permeability within the tumor may interfere with adequate delivery and retention of chemotherapeutic agents [54, 55]. Indeed, certain antiangiogenic agents that prevent tumor vessel leakage (a phenomenon called “vessel normalization”) were shown to enhance the delivery of chemotherapeutic agents into tumors . Thus, combination treatment with antiangiogenic factors together with conventional chemo-therapeutic agents may be superior to using the latter alone. Furthermore, because VEGF is likely required for migration and recruitment of ECs, T-oligo-me diated VEGF reduction would also likely decrease the number of blood vessels in the tumor [1, 6]. Our present findings suggest that T-oligos may induce potent antiangiogenic effects, enhancing their attractiveness as a therapeutic option for cancer.
In addition to VEGF and its receptors, angiopoietin 1 and 2 (ANG-1 and ANG-2) and their tyrosine kinase receptor Tie-2 have been identified as major players in the processes of growth and remodelling of tumor vasculature [57, 58]. ANG-1 activates the Tie-2 signalling pathway . Although under certain conditions ANG-2 may inhibit ANG-1 effect, in an in vivo mouse model for melanoma  and in glioma cells  increased expression of ANG-2 is thought to stimulate angiogenesis. Another angiogenic factor, HIF-1, a transcription factor that is activated by hypoxia, exerts its effect by upregulating VEGF levels. We found that T-oligo treatment inhibits HIF-1 activity and ANG-1 and ANG-2 expression in melanoma cell line and decreases VEGF synthesis secretion in these cells, strongly suggesting that T-oligo-mediated effects on tumor angiogenesis are transcriptional and ultimately affect several angiogenic molecules.
Our laboratory has previously shown that T-oligo increases p73 level in the p53 null MM-AN cells and that blocking p73 expression by RNAi decreases T-oligo-induced apoptosis in these cells . Like p53, p73 is known to inhibit angiogenesis, primarily through VEGF down-regulation . Therefore, we assume that in MM-AN cells T-oligo decreases VEGF production, in addition to its effect on HIF-1, by activating p73 through induction of E2F1. However, in cells with functional p53, we assume that T-oligo-induced p53 and p73 would cooperate to inhibit angiogenesis. Furthermore, E2F1 is known to induce apoptosis in part by its effect on p73. Thus, induction of E2F1 by T-oligos  also contributes to tumor cell apoptosis. E2F1 is reported to be upregulated by active (phosphorylated) ATM . We have previously shown that T-oligo treatment activates (phosphorylates) ATM [21, 27]. Moreover, the E2F1 promoter contains binding sites for E2F1 . We therefore suggest that T-oligo regulates E2F1 first via ATM-mediated phosphorylation of E2F1  and that E2F1 then further transcriptionally upregulates E2F1 by binding to its own promoter. Indeed, we show that T-oligo increases E2F1 mRNA and protein levels as well as its DNA binding activity in human MM-AN melanoma cells, further confirming our previous finding that E2F1contributes to T-oligo effects .
The T-oligos used in the present experiments have physiologic readily hydrolysable phosphodiester linkage, unlike for example antisense DNA in which phosphorothioate or other nonhydrolyzable linkage is employed to increase the molecule’s half-life (T 1/2). Hydrolyzable linkage is required for initiation of T-oligo signalling  and, despite the known short T 1/2, approximately 4–6 hours in serum-containing medium for a 12-base 100% telomere homolog , nevertheless this allows for the cellular responses observed in the present and previous experiments to evolve over 3–5 days [11, 13, 19, 21, 22, 24–28]. This may reflect the fact that at least in vitro T-oligos rapidly enter the nucleus [11, 22, 24, 27] and that, once in the nucleus, such oligos have a far longer T 1/2 . The efficacy of these presumptively short-lived T-oligos may also reflect the likelihood that, after interaction of the oligos with the Werner protein and formation of DNA damage-like foci at telomeres , signalling through the DNA damage response pathways may continue even if the T-oligos have been hydrolyzed, at least through 48 hours at which time the DNA damage foci can still be observed by immunohistochemistry .
In earlier studies, we have shown that T-oligos inhibit tumor growth in SCID mouse models by inducing cell cycle arrest, differentiation, apoptosis, and senescence [13, 15, 27]. We now show that T-oligos also inhibit angiogenesis. Angiogenesis inhibition encompassing both ECs and melanoma cells, in combination with other T-oligo-mediated anti-tumor effects [11, 13, 22, 25, 27], likely combine to significantly decrease melanoma burden in established SCID mouse models, as reported in our earlier publications [13, 27]. These multiple diverse responses are all mediated through activation and/or upregulation of DNA damage response proteins. They are thus reminiscent of the less complex but very well characterized bacterial SOS response, a genome-protective mechanism that enhances survival of prokaryotic organisms in the face of DNA damage . The telomere-based DNA damage-like signalling initiated by T-oligos may be viewed as an evolutionarily perfected parallel mechanism in mammalian cells that addresses the threat to genomic integrity posed by malignant transformation .
In summary, the present paper indicates that T-oligos exert multiple antiangiogenic effects. These data reinforce prior evidence that T-oligo therapy may offer a powerful new approach to treatment of human primary melanoma and possibly other human malignancies, with several conceptual advantages over the currently lionized targeted therapy approach .
Conflict of Interest
Aspects of this paper are patent-protected and licensed to SemaCo Inc., a for-profit company. Dr Gilchrest and Dr. Yaar are shareholders in SemaCo.
C. Coleman and D. Levine contributed equally to the paper. C. Coleman is currently affiliated with the University of New England and Danielle Levine, M.D., is dermatology resident at Harvard Medical School. This work was supported by grants from the NIH CA10515 (to BAG) and American Skin Association (to DL).
- J. Folkman, “Angiogenesis,” Annual Review of Medicine, vol. 57, pp. 1–18, 2006.
- N. Weidner, “New paradigm for vessel intravasation by tumor cells,” American Journal of Pathology, vol. 160, no. 6, pp. 1937–1939, 2002.
- C.-H. Chen, W. Jiang, D. P. Via et al., “Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression,” Circulation, vol. 101, no. 2, pp. 171–177, 2000.
- D. Bradbury, D. Clarke, C. Seedhouse, L. Corbettt, J. Stocks, and A. Knox, “Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP 2/EP4 receptors and SP-1 transcription factor binding sites,” Journal of Biological Chemistry, vol. 280, no. 34, pp. 29993–30000, 2005.
- G. Pagès and J. Pouysségur, “Transcriptional regulation of the Vascular Endothelial Growth Factor gene—a concert of activating factors,” Cardiovascular Research, vol. 65, no. 3, pp. 564–573, 2005.
- C. R. Tait and P. F. Jones, “Angiopoietins in tumours: the angiogenic switch,” Journal of Pathology, vol. 204, no. 1, pp. 1–10, 2004.
- Y. S. Park, N. H. Kim, and I. Jo, “Hypoxia and vascular endothelial growth factor acutely up-regulate angiopoietin-1 and Tie2 mRNA in bovine retinal pericytes,” Microvascular Research, vol. 65, no. 2, pp. 125–131, 2003.
- P. S. Ray, T. Estrada-Hernandez, H. Sasaki, L. Zhu, and N. Maulik, “Early effects of hypoxia/reoxygenation on VEGF, Ang-1, Ang-2 and their receptors in the rat myocardium: implications for myocardial angiogenesis,” Molecular and Cellular Biochemistry, vol. 213, no. 1-2, pp. 145–153, 2000.
- J. Stanelle, T. Stiewe, C. C. Theseling, M. Peter, and B. M. Pützer, “Gene expression changes in response to E2F1 activation,” Nucleic Acids Research, vol. 30, no. 8, pp. 1859–1867, 2002.
- V. Marwaha, Y.-H. Chen, E. Helms et al., “T-oligo treatment decreases constitutive and UVB-induced COX-2 levels through p53- and NFκB-dependent repression of the COX-2 promoter,” Journal of Biological Chemistry, vol. 280, no. 37, pp. 32379–32388, 2005.
- M. S. Eller, N. Puri, I. M. Hadshiew, S. S. Venna, and B. A. Gilchrest, “Induction of apoptosis by telomere overhang-specific DNA,” Experimental Cell Research, vol. 276, no. 2, pp. 185–193, 2002.
- G. Qin, R. Kishore, C. M. Dolan et al., “Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 29, pp. 11015–11020, 2006.
- N. Puri, M. S. Eller, H. R. Byers, S. Dykstra, J. Kubera, and B. A. Gilchrest, “Telomere-based DNA damage responses: a new approach to melanoma,” FASEB Journal, vol. 18, no. 12, pp. 1373–1381, 2004.
- M. Radman, “SOS repair hypothesis: phenomenology of an inducible DNA repair which is accompanied by mutagenesis,” Basic Life Sciences, vol. 5, pp. 355–367, 1975.
- B. A. Gilchrest and M. S. Eller, “The tale of the telomere: implications for prevention and treatment of skin cancers,” The Journal of Investigative Dermatology. Symposium Proceedings, vol. 10, no. 2, pp. 124–130, 2005.
- T. De Lange, “Protection of mammalian telomeres,” Oncogene, vol. 21, no. 4, pp. 532–540, 2002.
- E. L. Denchi and T. De Lange, “Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1,” Nature, vol. 448, no. 7157, pp. 1068–1071, 2007.
- S. Li, J. E. Rosenberg, A. A. Donjacour et al., “Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA,” Cancer Research, vol. 64, no. 14, pp. 4833–4840, 2004.
- H. Aoki, E. Iwado, M. S. Eller et al., “Telomere overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells,” FASEB Journal, vol. 21, no. 11, pp. 2918–2930, 2007.
- S. Arad, N. Konnikov, D. A. Goukassian, and B. A. Gilchrest, “T-oligos augment UV-induced protective responses in human skin,” The FASEB Journal, vol. 20, no. 11, pp. 1895–1897, 2006.
- M. S. Eller, G.-Z. Li, R. Firoozabadi, N. Puri, and B. A. Gilchrest, “Induction of a p95/Nbs1-mediated S phase checkpoint by telomere overhang specific DNA,” FASEB Journal, vol. 17, no. 2, pp. 152–162, 2003.
- M. S. Eller, X. Liao, S. Liu et al., “A role for WRN in telomere-based DNA damage responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 41, pp. 15073–15078, 2006.
- D. A. Goukassian, S. Bagheri, L. el-Keeb, M. S. Eller, and B. A. Gilchrest, “DNA oligonucleotide treatment corrects the age-associated decline in DNA repair capacity,” The FASEB Journal, vol. 16, no. 7, pp. 754–756, 2002.
- G.-Z. Li, M. S. Eller, R. Firoozabadi, and B. A. Gilchrest, “Evidence that exposure of the telomere overhang sequence induces senescence,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 527–531, 2003.
- G.-Z. Li, M. S. Eller, K. Hanna, and B. A. Gilchrest, “Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides,” Experimental Cell Research, vol. 301, no. 2, pp. 189–200, 2004.
- N. Ohashi, M. Yaar, M. S. Eller, F. Truzzi, and B. A. Gilchrest, “Features that determine telomere homolog oligonucleotide-induced therapeutic DNA damage-like responses in cancer cells,” Journal of Cellular Physiology, vol. 210, no. 3, pp. 582–595, 2007.
- M. Yaar, M. S. Eller, I. Panova et al., “Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells,” Breast Cancer Research, vol. 9, no. 1, article R13, 2007.
- H. O. Longe, P. B. Romesser, A. M. Rankin et al., “Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential,” International Journal of Cancer, vol. 124, no. 2, pp. 473–482, 2009.
- I. M. Hadshiew, M. S. Eller, F. P. Gasparro, and B. A. Gilchrest, “Stimulation of melanogenesis by DNA oligonucleotides: effect of size, sequence and phosphorylation,” Journal of Dermatological Science, vol. 25, no. 2, pp. 127–138, 2001.
- M. S. Eller, T. Maeda, C. Magnoni, D. Atwal, and B. A. Gilchrest, “Enhancement of DNA repair in human skin cells by thymidine dinucleotides: evidence for a p53-mediated mammalian SOS response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 23, pp. 12627–12632, 1997.
- D. A. Goukassian, M. S. Eller, M. Yaar, and B. A. Gilchrest, “Thymidine dinucleotide mimics the effect of solar simulated irradiation on p53 and p53-regulated proteins,” Journal of Investigative Dermatology, vol. 112, no. 1, pp. 25–31, 1999.
- P. L. Opresko, M. Otterlei, J. Graakjær et al., “The werner syndrome helicase and exonuclease cooperate to resolve telomeric D loops in a manner regulated by TRF1 and TRF2,” Molecular Cell, vol. 14, no. 6, pp. 763–774, 2004.
- R. Kishore, C. Luedemann, E. Bord, D. Goukassian, and D. W. Losordo, “Tumor necrosis factor-mediated E2F1 suppression in endothelial cells: differential requirement of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signal transduction pathways,” Circulation Research, vol. 93, no. 10, pp. 932–940, 2003.
- B. Salimath, D. Marmé, and G. Finkenzeller, “Expression of the vascular endothelial growth factor gene is inhibited by p73,” Oncogene, vol. 19, no. 31, pp. 3470–3476, 2000.
- H. R. Byers, T. Etoh, K. W. Lee, M. C. Mihm Jr., and S. Gattoni-Celli, “Organ-specific metastases in immunodeficient mice injected with human melanoma cells: a quantitative pathological analysis,” Melanoma Research, vol. 3, no. 4, pp. 247–253, 1993.
- K. F. Kusano, R. Pola, T. Murayama, et al., “Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling,” Nature Medicine, vol. 11, no. 11, pp. 1197–1204, 2005.
- D. A. Goukassian, G. Qin, C. Dolan et al., “Tumor necrosis factor-α receptor p75 is required in ischemia-induced neovascularization,” Circulation, vol. 115, no. 6, pp. 752–762, 2007.
- W. E. Wright, D. Brasiskyte, M. A. Piatyszek, and J. W. Shay, “Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids,” EMBO Journal, vol. 15, no. 7, pp. 1734–1741, 1996.
- D. Goukassian, A. Diez-Juan, T. Asahara et al., “Overexpression of by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis,” FASEB Journal, vol. 15, no. 11, pp. 1877–1885, 2001.
- J. Alroy, V. Goyal, and E. Skutelsky, “Lectin histochemistry of mammalian endothelium,” Histochemistry, vol. 86, no. 6, pp. 603–607, 1987.
- T. Asahara, D. Chen, T. Takahashi et al., “Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF- induced postnatal neovascularization,” Circulation Research, vol. 83, no. 3, pp. 233–240, 1998.
- B. Enholm, K. Paavonen, A. Ristimäki et al., “Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia,” Oncogene, vol. 14, no. 20, pp. 2475–2483, 1997.
- A. Albini, R. Benelli, D. M. Noonan, and C. Brigati, “The “chemoinvasion assay”: a tool to study tumor and endothelial cell invasion of basement membranes,” International Journal of Developmental Biology, vol. 48, no. 5-6, pp. 563–571, 2004.
- S. Dias, K. Hattori, B. Heissig et al., “Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10857–10862, 2001.
- B. Li, E. E. Sharpe, A. B. Maupin et al., “VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization,” The FASEB Journal, vol. 20, no. 9, pp. 1495–1497, 2006.
- R. Zhang, Y. Xu, N. Ekman et al., “Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway,” Journal of Biological Chemistry, vol. 278, no. 51, pp. 51267–51276, 2003.
- M. Detmar, L. F. Brown, K. P. Claffey et al., “Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis,” Journal of Experimental Medicine, vol. 180, no. 3, pp. 1141–1146, 1994.
- C.-C. Liu, Z. Shen, H.-F. Kung, and M. C. M. Lin, “Cancer gene therapy targeting angiogenesis: an updated review,” World Journal of Gastroenterology, vol. 12, no. 43, pp. 6941–6948, 2006.
- Z. K. Otrock, J. A. Makarem, and A. I. Shamseddine, “Vascular endothelial growth factor family of ligands and receptors: review,” Blood Cells, Molecules, and Diseases, vol. 38, no. 3, pp. 258–268, 2007.
- J. Folkman, “Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action,” Experimental Cell Research, vol. 312, no. 5, pp. 594–607, 2006.
- K. Holmes, O. L. Roberts, A. M. Thomas, and M. J. Cross, “Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition,” Cellular Signalling, vol. 19, no. 10, pp. 2003–2012, 2007.
- H. Zhong and J. P. Bowen, “Molecular design and clinical development of VEGFR kinase inhibitors,” Current Topics in Medicinal Chemistry, vol. 7, no. 14, pp. 1379–1393, 2007.
- H.-P. Gerber and N. Ferrara, “Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies,” Cancer Research, vol. 65, no. 3, pp. 671–680, 2005.
- V. F. Casneuf, P. Demetter, T. Boterberg, L. Delrue, M. Peeters, and N. Van Damme, “Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy,” Oncology Reports, vol. 22, no. 1, pp. 105–113, 2009.
- R. T. Tong, Y. Boucher, S. V. Kozin, F. Winkler, D. J. Hicklin, and R. K. Jain, “Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors,” Cancer Research, vol. 64, no. 11, pp. 3731–3736, 2004.
- R. K. Jain, “Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy,” Science, vol. 307, no. 5706, pp. 58–62, 2005.
- P. C. Maisonpierre, C. Suri, P. F. Jones et al., “Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis,” Science, vol. 277, no. 5322, pp. 55–60, 1997.
- S. Davis, T. H. Aldrich, P. F. Jones et al., “Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning,” Cell, vol. 87, no. 7, pp. 1161–1169, 1996.
- J. Pomyje, J. H. Živný, T. Stopka, J. Šimák, H. Vaňková, and E. Nečas, “Angiopoietin-1, angiopoietin-2 and Tie-2 in tumour and non-tumour tissues during growth of experimental melanoma,” Melanoma Research, vol. 11, no. 6, pp. 639–643, 2001.
- K. Koga, T. Todaka, M. Morioka et al., “Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis,” Cancer Research, vol. 61, no. 16, pp. 6248–6254, 2001.
- W.-C. Lin, F.-T. Lin, and J. R. Nevins, “Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation,” Genes and Development, vol. 15, no. 14, pp. 1833–1844, 2001.
- C. Y. Lin, Y. C. Liang, and B. Y.-M. Yung, “Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-κB, E2F1 and pRB,” Cellular Signalling, vol. 18, no. 11, pp. 2041–2048, 2006.
- Z. Cao, C.-C. Huang, and W. Tan, “Nuclease resistance of telomere-like oligonucleotides monitored in live cells by fluorescence anisotropy imaging,” Analytical Chemistry, vol. 78, no. 5, pp. 1478–1484, 2006.
- B. A. Gilchrest and M. S. Eller, “Cancer therapeutics: smart and smarter,” Drugs of the Future, vol. 34, no. 3, pp. 205–216, 2009.